Compare PLD & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLD | ABT |
|---|---|---|
| Founded | 1983 | 1888 |
| Country | United States | United States |
| Employees | 2802 | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0B | 152.9B |
| IPO Year | N/A | 2006 |
| Metric | PLD | ABT |
|---|---|---|
| Price | $143.63 | $90.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 20 |
| Target Price | ★ $140.78 | $130.90 |
| AVG Volume (30 Days) | 2.6M | ★ 9.6M |
| Earning Date | 04-16-2026 | 04-16-2026 |
| Dividend Yield | ★ 3.08% | 2.76% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $44,328,000,000.00 |
| Revenue This Year | $1.15 | $10.75 |
| Revenue Next Year | $6.12 | $8.10 |
| P/E Ratio | ★ $39.25 | $142.66 |
| Revenue Growth | N/A | ★ 5.67 |
| 52 Week Low | $103.41 | $81.97 |
| 52 Week High | $147.93 | $137.49 |
| Indicator | PLD | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 50.39 | 53.98 |
| Support Level | $139.08 | $84.96 |
| Resistance Level | $144.91 | $112.81 |
| Average True Range (ATR) | 2.50 | 1.89 |
| MACD | -0.54 | 0.80 |
| Stochastic Oscillator | 48.93 | 79.73 |
Prologis was formed by the 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.3 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party assets under management. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.